Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A (1)H-Magnetic Resonance Spectroscopy Study

BACKGROUND: Antiangiogenic treatment of glioblastomas with Bevacizumab lacks predictive markers. Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality. Since Bevacizumab markedly reduces tumor edema and influences the tumor microe...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:PLoS One
Asıl Yazarlar: Steidl, Eike, Pilatus, Ulrich, Hattingen, Elke, Steinbach, Joachim P., Zanella, Friedhelm, Ronellenfitsch, Michael W., Bähr, Oliver
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2016
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5198997/
https://ncbi.nlm.nih.gov/pubmed/28033329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0168113
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller